• Ashworth JL, Murphy G, Rock MJ, Sherratt MJ, Shapiro SD, Shuttleworth CA & Kielty CM (1999): Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J 340: 171181.
  • Ashworth JL, Kielty CM & McLeod D (2000): Fibrillin and the eye. Br J Ophthalmol 84: 13121317.
  • Findl O, Kriechbaum K, Sacu S, Kiss B, Polak K & Nepp J (2003): Influence of operator experience on the performance of ultrasound biometry compared to optical biometry before cataract surgery. J Cataract Refract Surg 29: 19501955.
  • Gutierrez-Ortiz C, Teus MA & Bolivar G (2006): Short-term effects of latanoprost on anterior chamber depth in patients with glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 47: 48564859.
  • Hashemi H, Yazdani K, Mehravaran S & Fotouhi A (2005): Anterior chamber depth measurement with A-scan ultrasonography, Orbscan II, and IOLMaster. Optom Vis Sci 82: 900904.
  • Huang SH, Adamis AP, Wiederschain DG, Shima DT, Shing Y & Moses MA (1996): Matrix metalloproteinases and their inhibitors in aqueous humour. Exp Eye Res 62: 481490.
  • Kashiwagi K & Weinreb RN (1997): Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 38: 22142223.
  • Lee PS, Gagliuso DJ & Serle JB (2007): Medical therapy for glaucoma. In: ChoplinNT & LundyDC (eds) Atlas of Glaucoma. Informa UK Ltd, London, UK, 221238.
  • Los LI, van der Worp RJ, van Luyn MJ & Hooymans JM (2004): Presence of collagen IV in the ciliary zonules of the human eye: an immunohistochemical study. J Histochem Cytochem 52: 789795.
  • Marchini G, Ghilotti G, Bonadimani M & Babighian S (2003): Effects of 0.005% latanoprost on ocular anterior structures and ciliary body thickness. J Glaucoma 12: 295300.
  • Nagase H & Woessner JF (1999): Matrix metalloproteinases. J Biol Chem 274: 2149121494.
  • Olsen T, Arnarsson A, Sasaki H, Sasaki K & Jonasson F (2007): On the ocular refractive components: the Reykjavik Eye Study. Acta Ophthalmol Scand 85: 361366.
  • Poyer JF, Millar C & Kaufman PL (1995): Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 36: 24612465.
  • Sagara T, Gaton D, Lindsey JD, Gabelt BT, Kaufman PL & Weinreb RN (1999): Topical prostaglandin F2 alpha treatment reduces collagen type I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 117: 794801.
  • Sohajda Z, Papp J, Berta A & Módis L (2008): The comparative study of two recently developed A-scan devices: determination of central corneal thickness, anterior chamber depth and axial length. Acta Ophthalmol 86: 4548.
  • Vogel A, Dick HB & Krummenauer F (2001): Reproducibility of optical biometry using partial coherence interferometry: intraobserver and interobserver reliability. J Cataract Refract Surg 27: 19611968.
  • Weinreb RN & Lindsey JD (2002): Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 43: 716722.
  • Weinreb RN, Toris CB, Gabelt BT, Lindsey JD & Kaufman PL (2002): Effects of prostaglandins on the aqueous humour outflow pathways. Surv Ophthalmol 47 (Suppl. 1): 4364.
  • Weinreb RN, Lindsey JD, Marchenko G, Marchenko N, Angert M & Strongin A (2004): Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci 45: 43674377.
  • Yamaji K, Yoshitomi T, Ishikawa H & Usui S (2005): Prostaglandins E1 and E2, but not F2α or latanoprost, inhibit monkey ciliary muscle contraction. Curr Eye Res 30: 661665.